<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mimmun</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинская иммунология</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Immunology (Russia)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1563-0625</issn><issn pub-type="epub">2313-741X</issn><publisher><publisher-name>SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15789/1563-0625-ROG-2287</article-id><article-id custom-type="elpub" pub-id-type="custom">mimmun-2287</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>МАТЕРИАЛЫ ФОРУМА "ДНИ ИММУНОЛОГИИ В СПБ" 2021</subject></subj-group></article-categories><title-group><article-title>РОЛЬ GSK-3 В Wnt/β-CATENIN-СИГНАЛЬНОМ ПУТИ ПРИ ОЖИРЕНИИ</article-title><trans-title-group xml:lang="en"><trans-title>ROLE OF GSK-3 IN Wnt/β-CATENIN SIGNALING PATHWAY IN OBESITY</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5828-8620</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кулакова</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Kulakova</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>врач-гастроэнтеролог,</p><p>241033, г. Брянск, пр. Станке Димитрова, 86</p></bio><bio xml:lang="en"><p>Gastroenterologist,</p><p>241033, Bryansk, Stanko Dimitrov ave., 86</p></bio><email xlink:type="simple">Kulakovaas@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4258-963X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Снимщикова</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Snimshchikova</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор, заведующая кафедрой иммунологии и специализированных клинических дисциплин, директор Медицинского института,</p><p>г. Орел</p></bio><bio xml:lang="en"><p>PhD, MD (Medicine), Professor, Head, Department of Immunology and Clinical Specialties, Director of the Medical Institute, </p><p>Orel</p></bio><email xlink:type="simple">snimshikova@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1593-5290</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Плотникова</surname><given-names>М. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Plotnikova</surname><given-names>M. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>старший преподаватель кафедры иммунологии и специализированных клинических дисциплин Медицинского института,</p><p>г. Орел</p></bio><bio xml:lang="en"><p>Senior Lecturer, Department of Immunology and Clinical Specialties of the Medical Institute, </p><p>Orel</p></bio><email xlink:type="simple">moplotnikova@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГАУЗ «Брянская областная больница № 1»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Bryansk Regional Hospital No. 1</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Орловский государственный университет имени И.С. Тургенева»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I. Turgenev Oryol State University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>08</day><month>10</month><year>2021</year></pub-date><volume>23</volume><issue>4</issue><fpage>775</fpage><lpage>780</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Кулакова А.С., Снимщикова И.А., Плотникова М.О., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Кулакова А.С., Снимщикова И.А., Плотникова М.О.</copyright-holder><copyright-holder xml:lang="en">Kulakova A.S., Snimshchikova I.A., Plotnikova M.O.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.mimmun.ru/mimmun/article/view/2287">https://www.mimmun.ru/mimmun/article/view/2287</self-uri><abstract><p>На механизм адипогенеза оказывают влияние многочисленное количество факторов, важными из них являются компоненты Wnt-сигнального пути. Поиск возможных маркеров развития заболеваний, связанных с ожирением, обусловил интерес к изучению GSK-3 (glycogensyntase kinase), β-катенина. GSK-3β – внутриклеточная серин/треониновая киназа, обнаружена в цитоплазме, ядре, митохондриях, синтезируется во всех тканях организма и участвует в регуляции таких процессов, как метаболизм, клеточная пролиферация, апоптоз и другие. GSK-3β в активном состоянии фосфорилирует и ингибирует гликогенсинтазу. Когда инсулин связывается с рецептором на клетке через инозитол-3-фосфат, то активация протеинкиназа В(Akt1) активируется и, в свою очередь, фосфорилирует и ингибирует GSK-3β. Также GSK-3β участвует в регуляции обмена глюкозы. Важная функция GSK-3β – ингибирование белка β-катенина. Когда клетка GSK-3β в комплексе с белками APC и Axin покоится, то происходит связывание и фосфолирование транскрипционного фактора β-катенина, затем его убиквинтирование и деградация. Когда Wnt действует на клетку белков, то белок Dvl активируется, связывается с GSK-3β, высвобождая β-катенин, что препятствует его распаду. При этом роль GSK3α/β в воспалительной реакции адипоцитов до сих пор полностью не исследована, поэтому представляется перспективным изучение места GSK-3 в Wnt/β-catenin-сигнальном пути при ожирении.</p><p>Целью исследования явилась оценка активности компонентов Wnt-сигнального пути у пациентов с ожирением посредством определения уровня GSK-3 и β-катенина в сыворотке крови. В исследование были включены 32 пациента, у которых было определено ожирение I-III степени с прогрессирующими формами, сахарный диабет отсутствует. Чтобы определить концентацию GSK-3α, GSK-3β и β-катенина в сыворотке крови, был использован метод иммуноферментного анализа. Данные представлены в виде абсолютного и относительного (%) числа больных; среднего арифметического; медианы, 1-го и 3-го квартилей – Ме (Q0,25-Q0,75). В сыворотке крови пациентов, страдающих ожирением, выявлено повышение уровня GSK-3α (785 (371-1317,5) пг/мл) в 7,5 раз по сравнению со здоровыми лицами 105 (102,5-110) пг/мл, (р &lt; 0,001), также повышение уровня GSK – 3β в сыворотке крови, уровень которого у пациентов с ожирением составил 295 (190-695) пг/мл, что на 18,3% превышало аналогичные показатели, полученные у здоровых лиц 241 (218,75-287,5) пг/мл, р = 0,111. Была отмечена тенденция к увеличению количества GSK-3 в зависимости от степени ожирения, при этом часто наблюдается снижение β-катенина, что согласуется с исследованиями ряда авторов. Эти данные можно рассматривать в качестве прогностического критерия течения патологических процессов при ожирении. </p></abstract><trans-abstract xml:lang="en"><p>The complexity of the adipogenesis mechanism results from the impact of multiple cues, among which an important place is held by the components of the Wnt signaling pathway. The search for potential markers of the development of diseases related to obesity aroused an interest in the study of GSK-3 (glycogen synthase kinase), β-catenin. GSK-3β is an intracellular serine / threonine kinase found in the cytoplasm, nucleus, mitochondria, synthesized in all body tissues and involved in regulating metabolic processes, cell proliferation, apoptosis etc. The first of the discovered functions of GSK-3β was the regulation of glycogen synthesis. Active GSK-3β phosphorylates and thereby inhibits glycogen synthase. As a result of the insulin binding to the cell receptor via inositol-3-phosphate, protein kinase B (Akt1) is activated, which, in turn, phosphorylates and inhibits GSK-3β. In addition, GSK-3β is involved in the regulating glucose metabolism. The most important function of GSK-3β is the inhibition of the β-catenin protein. In a resting cell, GSK-3β in complex with the APC and Axin proteins binds and phosphorylates the β-catenin transcription factor, which leads to its ubiquitination and degradation. When Wnt proteins act on the cell, the Dvl protein is activated, which, by binding to GSK-3β, releases β-catenin, preventing its degradation, however, the role of GSK3α/β in the adipocyte inflammatory response has not yet been fully investigated, therefore it seems promising to study the role of GSK-3 in the Wnt/β-catenin signaling pathway in obesity</p><p>The aim of the study was to assess the activity of the components of the Wnt signaling pathway in obese patients by measuring the serum level of GSK-3 and β-catenin. There were enrolled 32 patients with progressive forms of I-III degree obesity in the absence of diabetes mellitus. The concentration of serum GSK-3α, GSK-3β, and β-catenin was measured by enzyme-linked immunoassay. Data are presented as absolute and relative (%) number of patients; arithmetic mean; medians, 1 and 3 quartiles – Ме (Q0.25-Q0.75). Obese patients contained a 7.5-fold increased serum level of GSK-3α (785 (371-1317.5) pg/ml) compared to healthy individuals 105 (102.5-110) pg/ml, (p &lt; 0.001), paralleled with increased amount of GSK-3β, which level in obese patients was 295 (190-695) pg/ml, which is by 18.3% higher than those in healthy individuals 241 (218.75-287.5) pg/ml, p = 0.111. Amount of GSK-3 depending on the degree of obesity tended to increase, most often coupled to decreased β-catenin level which is consistent with the literature data and can be considered as a prognostic criterion for the course of pathological processes in obesity. </p></trans-abstract><kwd-group xml:lang="ru"><kwd>ожирение</kwd><kwd>GSK-3α</kwd><kwd>GSK-3β</kwd><kwd>β-катенин</kwd><kwd>Wnt-сигнальный путь</kwd></kwd-group><kwd-group xml:lang="en"><kwd>obesity</kwd><kwd>GSK-3α</kwd><kwd>GSK-3β</kwd><kwd>β-catenin</kwd><kwd>Wnt- signaling pathway</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ackers I., Malgor R. Interrelationship of canonical and non-canonical Wnt signalling pathways in chronic metabolic diseases. Diabetes Vasc. Dis. Res., 2018, Vol. 15, no. 1, pp. 3-13.</mixed-citation><mixed-citation xml:lang="en">Ackers I., Malgor R. Interrelationship of canonical and non-canonical Wnt signalling pathways in chronic metabolic diseases. Diabetes Vasc. Dis. Res., 2018, Vol. 15, no. 1, pp. 3-13.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Ahmad B., Serpell C.J., Fong I.L., Wong E.H. Molecular Mechanisms of Adipogenesis: The Anti-adipogenic Role of AMP-Activated Protein Kinase. Front. Mol. Biosci., 2020, no. 7, 76. doi: 10.3389/fmolb.2020.00076.</mixed-citation><mixed-citation xml:lang="en">Ahmad B., Serpell C.J., Fong I.L., Wong E.H. Molecular Mechanisms of Adipogenesis: The Anti-adipogenic Role of AMP-Activated Protein Kinase. Front. Mol. Biosci., 2020, no. 7, 76. doi: 10.3389/fmolb.2020.00076.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Beurel E., Grieco S.F, Jope R.S. Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol. Ther., 2015, no. 148, pp. 114-131.</mixed-citation><mixed-citation xml:lang="en">Beurel E., Grieco S.F, Jope R.S. Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol. Ther., 2015, no. 148, pp. 114-131.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Cawthorn W.P., Bree A.J., Yao Y., Du B., Hemati N., Martinez-Santibañez G., MacDougald O.A. Wnt6, Wnt10a and Wnt10b inhibit adipogenesis and stimulate osteoblastogenesis through a β-catenin-dependent mechanism. J. Bone, 2012, Vol. 50, no. 2, pp. 477-489.</mixed-citation><mixed-citation xml:lang="en">Cawthorn W.P., Bree A.J., Yao Y., Du B., Hemati N., Martinez-Santibañez G., MacDougald O.A. Wnt6, Wnt10a and Wnt10b inhibit adipogenesis and stimulate osteoblastogenesis through a β-catenin-dependent mechanism. J. Bone, 2012, Vol. 50, no. 2, pp. 477-489.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Chen D., Xie R., Shu B., Landay A. L. Wei C., Reiser J., Spagnoli A., Torquati A., Forsyth C.B., Keshavarzian A., Sumner D.R. Wnt signaling in bone, kidney, intestine, and adipose tissue and inter-organ interaction in aging. Ann. N. Y. Acad. Sci., 2019, Vol. 1442, no. 1, pp. 48-60.</mixed-citation><mixed-citation xml:lang="en">Chen D., Xie R., Shu B., Landay A. L. Wei C., Reiser J., Spagnoli A., Torquati A., Forsyth C.B., Keshavarzian A., Sumner D.R. Wnt signaling in bone, kidney, intestine, and adipose tissue and inter-organ interaction in aging. Ann. N. Y. Acad. Sci., 2019, Vol. 1442, no. 1, pp. 48-60.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Christodoulides C. Lagathu C., Sethi J.K., Vidal-Puig A. Adipogenesis and WNT signaling. Trends Endocrinol. Metab., 2009, Vol. 20, no. 1, pp. 16-24.</mixed-citation><mixed-citation xml:lang="en">Christodoulides C. Lagathu C., Sethi J.K., Vidal-Puig A. Adipogenesis and WNT signaling. Trends Endocrinol. Metab., 2009, Vol. 20, no. 1, pp. 16-24.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Cline G.W., Johnson K., Regittnig W., Perret P., Tozzo E., Xiao L., Damico C., Shulman G.I. Effects of a novel glycogen synthase kinase-3 inhibitor on insulin-stimulated glucose metabolism in Zucker diabetic fatty (falfa) rats. Diabetes, 2002, Vol. 51, no. 10, pp. 2903-2910.</mixed-citation><mixed-citation xml:lang="en">Cline G.W., Johnson K., Regittnig W., Perret P., Tozzo E., Xiao L., Damico C., Shulman G.I. Effects of a novel glycogen synthase kinase-3 inhibitor on insulin-stimulated glucose metabolism in Zucker diabetic fatty (falfa) rats. Diabetes, 2002, Vol. 51, no. 10, pp. 2903-2910.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Colomiere M., Permezel M., Lappas M. Diabetes and obesity during pregnancy alter insulin signalling and glucose transporter expression in maternal skeletal muscle and subcutaneous adipose tissue. J. Mol. Endocrinol., 2010, Vol. 44, no. 4, pp. 213-223.</mixed-citation><mixed-citation xml:lang="en">Colomiere M., Permezel M., Lappas M. Diabetes and obesity during pregnancy alter insulin signalling and glucose transporter expression in maternal skeletal muscle and subcutaneous adipose tissue. J. Mol. Endocrinol., 2010, Vol. 44, no. 4, pp. 213-223.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Doble B.W., Woodgett J.R. GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci., 2003. Vol. 116, no. 7, pp. 1175-1186.</mixed-citation><mixed-citation xml:lang="en">Doble B.W., Woodgett J.R. GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci., 2003. Vol. 116, no. 7, pp. 1175-1186.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Lappas M. Is increased in adipose tissue and skeletal muscle from women with gestational diabetes where it regulates the inflammatory response. PLoS One, 2014, Vol. 9, no. 12, e115854. doi: 10.1371/journal.pone.0115854.</mixed-citation><mixed-citation xml:lang="en">Lappas M. Is increased in adipose tissue and skeletal muscle from women with gestational diabetes where it regulates the inflammatory response. PLoS One, 2014, Vol. 9, no. 12, e115854. doi: 10.1371/journal.pone.0115854.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Markussen L.K., Winther S., Wicksteed B., Hansen J.B. GSK3 is a negative regulator of the thermogenic program in brown adipocytes. Sci. Rep., 2018, Vol. 8, no. 1, 3469. doi: 10.1038/s41598-018-21795-y.</mixed-citation><mixed-citation xml:lang="en">Markussen L.K., Winther S., Wicksteed B., Hansen J.B. GSK3 is a negative regulator of the thermogenic program in brown adipocytes. Sci. Rep., 2018, Vol. 8, no. 1, 3469. doi: 10.1038/s41598-018-21795-y.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Ng L.F., Kaur P., Bunnag N., Suresh J., Sung I., Tan Q.H., Gruber J., Tolwinski N.S. WNT Signaling in Disease. Cells, 2019, Vol. 8, no. 8, pp. 826-857.</mixed-citation><mixed-citation xml:lang="en">Ng L.F., Kaur P., Bunnag N., Suresh J., Sung I., Tan Q.H., Gruber J., Tolwinski N.S. WNT Signaling in Disease. Cells, 2019, Vol. 8, no. 8, pp. 826-857.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Rayasam G.V., Tulasi V.K., Sodhi R., Davis J.A., Ray A. Glycogen synthase kinase 3: more than a namesake. J. Pharmacol., 2009, Vol. 156, no. 6, pp. 885-898.</mixed-citation><mixed-citation xml:lang="en">Rayasam G.V., Tulasi V.K., Sodhi R., Davis J.A., Ray A. Glycogen synthase kinase 3: more than a namesake. J. Pharmacol., 2009, Vol. 156, no. 6, pp. 885-898.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Shen H.H., Yang C.Y., Kung C.W., Chen S.Y., Wu H.M., Cheng P.Y., Lam K.K., Lee Y.M. Raloxifene inhibits adipose tissue inflammation and adipogenesis through Wnt regulation in ovariectomized rats and 3T3-L1 cells. J. Biomed. Sci., 2019, Vol. 26, no. 62.</mixed-citation><mixed-citation xml:lang="en">Shen H.H., Yang C.Y., Kung C.W., Chen S.Y., Wu H.M., Cheng P.Y., Lam K.K., Lee Y.M. Raloxifene inhibits adipose tissue inflammation and adipogenesis through Wnt regulation in ovariectomized rats and 3T3-L1 cells. J. Biomed. Sci., 2019, Vol. 26, no. 62.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Wang L., Li X., Wang Y. GSK3β inhibition attenuates LPS-induced IL-6 expression in porcine adipocytes. Sci. Rep., 2018, Vol. 8, no. 1, e15967. doi: 10.1038/s41598-018-34186-0.</mixed-citation><mixed-citation xml:lang="en">Wang L., Li X., Wang Y. GSK3β inhibition attenuates LPS-induced IL-6 expression in porcine adipocytes. Sci. Rep., 2018, Vol. 8, no. 1, e15967. doi: 10.1038/s41598-018-34186-0.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
